inclusion criteria: male or female. aged 18 and older. have either type i or type ii diabetes mellitus. hospitalised with suspected or confirmed novel coronavirus (severe acute respiratory syndrome coronavirus 2 (sars-cov-2)) infection at time of enrolment, categorised as stage 3, 4 or 5 on the who ordinal scale for clinical improvement. blood glucose level at or above 4 mmol/l. able to take oral (tablet) formulation of medication. patient is able to provide written informed consent prior to initiation of any study procedures.

inclusion criteria: male or female. aged 18 and older. have either type i or type ii diabetes mellitus. hospitalised with suspected or confirmed novel coronavirus (severe acute respiratory syndrome coronavirus 2 (sars-cov-2)) infection at time of enrolment, categorised as stage 3, 4 or 5 on the who ordinal scale for clinical improvement. blood glucose level at or above 4 mmol/l. able to take oral (tablet) formulation of medication. patient is able to provide written informed consent prior to initiation of any study procedures.

inclusion criteria: 1. male or female. 2. aged 18 and older. 3. have either type i or type ii diabetes mellitus. 4. hospitalised with suspected or confirmed novel coronavirus (severe acute respiratory syndrome coronavirus 2 (sars-cov-2)) infection at time of enrolment, categorised as stage 3, 4 or 5 on the who ordinal scale for clinical improvement. 5. blood glucose level at or above 4 mmol/l. 6. able to take oral (tablet) formulation of medication. 7. patient is able to provide written informed consent prior to initiation of any study procedures.

inclusion criteria: 1. male or female. 2. aged 18 and older. 3. have either type i or type ii diabetes mellitus. 4. hospitalised with suspected or confirmed novel coronavirus (severe acute respiratory syndrome coronavirus 2 (sars-cov-2)) infection at time of enrolment, categorised as stage 3, 4 or 5 on the who ordinal scale for clinical improvement. 5. blood glucose level at or above 4 mmol/l. 6. able to take oral (tablet) formulation of medication. 7. patient is able to provide written informed consent prior to initiation of any study procedures.